Downregulation of XXXX and @entity13490 expression in blood following bariatric surgery.

@entity2175 @entity1 @entity6 @entity28 @entity13490 @entity1243
BACKGROUND: @entity2175 ( @entity2175 ) resolves rapidly after bariatric surgery, even before substantial weight is lost. However, the molecular pathways underlying this phenomenon remain unclear. Microarray data has shown that numerous genes are differentially expressed in blood after bariatric surgery, including @entity13490 and @entity1243 . @entity13490 and @entity1243 are circulating hormones derived from adipose tissue, which are associated with @entity28 and insulin resistance. This study examined expression of these genes before and after bariatric surgery in @entity6 @entity1 . METHODS: The study included 16 @entity28 @entity1 who underwent bariatric surgery, either Roux-en-Y gastric bypass (RYGB) or adjustable gastric banding. Eight @entity1 had @entity2175 . Preoperative blood samples were collected in PAXgene tubes to stabilize mRNA. Postoperative samples were collected 3 months after surgery. Total RNA was isolated and cDNA was synthesized. Real-time quantitative PCR was used to quantify mRNA. Results were analyzed using Student's t test with a P<0.05 considered significant. RESULTS: Postoperatively, five @entity6 @entity1 had discontinued hypoglycemic medications and one showed improved glycemic control. Both @entity1243 and @entity13490 mRNA levels were elevated in the @entity6 group but decreased after surgery to levels near those of the nondiabetic group. Greater downregulation of @entity13490 and @entity1243 expression occurred in @entity1 who lost more excess body weight (EBW), while @entity1 who lost less than 10% EBW had a mean increase in expression of the two genes. Downregulation of both genes was more pronounced after RYGB compared to gastric banding. CONCLUSIONS: Downregulation of @entity13490 and @entity1243 gene expression after bariatric surgery may play a role in normalizing @entity28 -associated insulin resistance. Interestingly, downregulation is greater after RYGB and in @entity1 who lose a greater proportion of EBW. Targeted therapies for @entity28 and @entity6 may be developed by understanding the pathways by which these adipocytokines contribute to @entity28 and @entity2175 .
